JP2005515407A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005515407A5 JP2005515407A5 JP2003542897A JP2003542897A JP2005515407A5 JP 2005515407 A5 JP2005515407 A5 JP 2005515407A5 JP 2003542897 A JP2003542897 A JP 2003542897A JP 2003542897 A JP2003542897 A JP 2003542897A JP 2005515407 A5 JP2005515407 A5 JP 2005515407A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- subject
- inhibitor
- apparently healthy
- reducing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 2
- 102000015427 Angiotensins Human genes 0.000 claims 1
- 108010064733 Angiotensins Proteins 0.000 claims 1
- 102400000432 CD40 ligand, soluble form Human genes 0.000 claims 1
- 101800000267 CD40 ligand, soluble form Proteins 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 claims 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims 1
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- -1 antiplatelet agent Substances 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 229960004676 antithrombotic agent Drugs 0.000 claims 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 230000007211 cardiovascular event Effects 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 239000003527 fibrinolytic agent Substances 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000003087 receptor blocking agent Substances 0.000 claims 1
- 108091006082 receptor inhibitors Proteins 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33884101P | 2001-11-05 | 2001-11-05 | |
| PCT/US2002/035505 WO2003040691A2 (en) | 2001-11-05 | 2002-11-05 | Soluble cd40l(cd154) as a prognostic marker of atherosclerotic diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005515407A JP2005515407A (ja) | 2005-05-26 |
| JP2005515407A5 true JP2005515407A5 (https=) | 2006-04-20 |
Family
ID=23326383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003542897A Pending JP2005515407A (ja) | 2001-11-05 | 2002-11-05 | アテローム硬化症の予後マーカーとしての可溶性ｃｄ４０ｌ（ｃｄ１５４） |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7189518B2 (https=) |
| EP (1) | EP1451577A4 (https=) |
| JP (1) | JP2005515407A (https=) |
| KR (1) | KR20040068544A (https=) |
| CN (1) | CN1613012A (https=) |
| CA (1) | CA2464531A1 (https=) |
| WO (1) | WO2003040691A2 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6727102B1 (en) * | 1997-06-20 | 2004-04-27 | Leuven Research & Development Vzw | Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins |
| US6309888B1 (en) * | 1998-09-04 | 2001-10-30 | Leuven Research & Development Vzw | Detection and determination of the stages of coronary artery disease |
| WO2002012266A1 (en) | 2000-08-05 | 2002-02-14 | Glaxo Group Limited | 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents |
| US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
| US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| GB0019172D0 (en) | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
| US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| WO2002018324A2 (en) | 2000-08-29 | 2002-03-07 | Nobex Corporation | Immunoregulatory compounds, derivatives thereof and their use |
| UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
| PT1383786E (pt) | 2001-04-30 | 2008-12-30 | Glaxo Group Ltd | Derivados anti-inflamatórios de éster 17.beta-carbotioato de androstano com um grupo éster ciclíco na posição 17.alfa |
| US7642286B2 (en) * | 2001-06-21 | 2010-01-05 | Andrx Pharmaceuticals, Inc. | Stable pharmaceutical compositions containing pravastatin |
| US8048924B2 (en) * | 2001-08-29 | 2011-11-01 | Biocon Limited | Methods and compositions employing 4-aminophenylacetic acid compounds |
| JP2005515407A (ja) * | 2001-11-05 | 2005-05-26 | ザ ブライアム アンド ウィミンズ ホスピタル インコーポレーテッド | アテローム硬化症の予後マーカーとしての可溶性ｃｄ４０ｌ（ｃｄ１５４） |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| ATE394679T1 (de) * | 2002-11-16 | 2008-05-15 | Dade Behring Marburg Gmbh | Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen |
| EP1530047A1 (en) * | 2003-11-07 | 2005-05-11 | Roche Diagnostics GmbH | Proximal markers of arterial thrombosis and inflammation for risk stratification of coronary heart disease |
| US20050181451A1 (en) * | 2004-02-12 | 2005-08-18 | Bates Harold M. | Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants |
| WO2005087266A1 (en) * | 2004-03-05 | 2005-09-22 | Vddi Pharmaceuticals | Combination therapy for inhibition of platelet aggregation |
| WO2005110422A2 (en) * | 2004-05-19 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Treatment of diseases associated with altered level of amyloid beta peptides |
| DE102004028303A1 (de) | 2004-06-11 | 2005-12-29 | Roche Diagnostics Gmbh | Verfahren und Vorrichtung zum Nachweis von Analyten |
| EP1615035B1 (en) * | 2004-07-07 | 2007-06-06 | F.Hoffmann-La Roche Ag | Multimarker panel for diabetes type 1 and 2 |
| DK1773767T3 (en) | 2004-07-07 | 2016-03-21 | Biocon Ltd | Synthesis of azo bound in immune regulatory relations |
| US7560227B2 (en) * | 2005-02-28 | 2009-07-14 | University Of Massachusetts | Biomarkers of vulnerable atherosclerotic plaques and methods of use |
| WO2007042778A2 (en) * | 2005-10-11 | 2007-04-19 | St George's Enterprises Limited | Monitoring cardiovascular disease by determining the expression of kir2ds2 and/or dap12 |
| EP2431746A1 (en) | 2005-11-17 | 2012-03-21 | Biogen Idec MA Inc. | Platelet aggregation assays |
| EP2302395B1 (en) | 2006-06-07 | 2015-04-15 | Health Diagnostic Laboratory, Inc. | Markers associated with arteriovascular events and methods of use thereof |
| US20120034629A1 (en) * | 2007-08-17 | 2012-02-09 | Siemens Healthcare Diagnostics Inc. | Prediction of non-fatal and fatal atherothrombotic events |
| US9359633B2 (en) * | 2007-11-05 | 2016-06-07 | Nordic Bioscience A/S | Biochemical markers for CVD risk assessment |
| AU2010324544A1 (en) | 2009-11-27 | 2012-06-21 | Baker Idi Heart And Diabetes Institute Holdings Limited | Lipid biomarkers for stable and unstable heart disease |
| US20190263888A1 (en) | 2010-10-19 | 2019-08-29 | Op-T Llc | Therapeutic peptides and methods for treating autoimmune related disease |
| JP5857312B2 (ja) * | 2011-08-11 | 2016-02-10 | 積水メディカル株式会社 | 心疾患診断マーカー |
| CN103163295B (zh) * | 2011-12-08 | 2015-11-18 | 吴宗贵 | 一种用于急性冠脉综合征的液相芯片试剂盒以其制备方法 |
| MX382403B (es) * | 2012-08-16 | 2025-03-13 | Critical Care Diagnostics Inc | Métodos para predecir el riesgo de desarrollar hipertensión. |
| EP2968292A4 (en) * | 2013-03-15 | 2016-11-23 | Intermune Inc | METHOD FOR IMPROVING MICROVASCULAR INTEGRITY |
| ES3031007T3 (en) * | 2017-11-10 | 2025-07-03 | Op T Llc | Peptide for preventing, modulating and/or reducing cardiovascular disease |
| US11793854B2 (en) | 2019-03-21 | 2023-10-24 | Op-T Llc | Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction |
| US12048734B2 (en) | 2020-04-17 | 2024-07-30 | Op-T Llc | Bioactive peptides and methods of use thereof |
| JP7584125B2 (ja) | 2020-11-02 | 2024-11-15 | 国立大学法人千葉大学 | 心血管イベントの発症リスクの検査方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5358844A (en) * | 1993-02-18 | 1994-10-25 | Brigham And Women's Hospital, Inc. | Preservation of blood platelets |
| US5622867A (en) * | 1994-10-19 | 1997-04-22 | Lifecell Corporation | Prolonged preservation of blood platelets |
| US5919614A (en) * | 1994-10-19 | 1999-07-06 | Lifecell Corporation | Composition comprising three platelet lesion inhibitors for platelet storage |
| WO1998020155A1 (en) * | 1996-11-08 | 1998-05-14 | New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Diagnostic methods using cd40 ligand assay |
| ATE530180T1 (de) | 1997-04-02 | 2011-11-15 | Brigham & Womens Hospital | Verfahren zur ermittlung der individualen risikoprofile atherosklerotischen erkrankungen |
| US6117911A (en) * | 1997-04-11 | 2000-09-12 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
| AU782386C (en) | 1999-08-31 | 2006-08-10 | Brigham And Women's Hospital | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases |
| JP2001322933A (ja) | 2000-05-15 | 2001-11-20 | Ucb Sa | Ｃｄ４０シグナル遮断剤 |
| JP2005515407A (ja) * | 2001-11-05 | 2005-05-26 | ザ ブライアム アンド ウィミンズ ホスピタル インコーポレーテッド | アテローム硬化症の予後マーカーとしての可溶性ｃｄ４０ｌ（ｃｄ１５４） |
-
2002
- 2002-11-05 JP JP2003542897A patent/JP2005515407A/ja active Pending
- 2002-11-05 EP EP02780578A patent/EP1451577A4/en not_active Ceased
- 2002-11-05 CN CNA028267117A patent/CN1613012A/zh active Pending
- 2002-11-05 WO PCT/US2002/035505 patent/WO2003040691A2/en not_active Ceased
- 2002-11-05 US US10/288,253 patent/US7189518B2/en not_active Expired - Fee Related
- 2002-11-05 CA CA002464531A patent/CA2464531A1/en not_active Abandoned
- 2002-11-05 KR KR10-2004-7006789A patent/KR20040068544A/ko not_active Withdrawn
-
2007
- 2007-03-12 US US11/716,996 patent/US20080058360A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005515407A5 (https=) | ||
| EP1799269A4 (en) | OLIGORIBONUCLEOTIDES AND METHOD OF USE THEREOF FOR THE TREATMENT OF ALOPEZIA, AKUTER NIERENINSUFFIZIENZ AND OTHER DISORDERS | |
| WO2003060659A3 (en) | Multi-note method and system for loans based upon lease revenue stream | |
| NZ506188A (en) | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof | |
| SG147294A1 (en) | Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy. | |
| ID29930A (id) | Senyawa-senyawa triazol dan penggunaannya | |
| WO2002022627A3 (en) | Ligands for metabotropic glutamate receptors | |
| PL350786A1 (en) | Cell adhesion−inhibiting antiinflammatory and immune−suppressive compounds | |
| WO2003104273A3 (en) | Therapeutic epitopes and uses thereof | |
| ES2619332T3 (es) | Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma | |
| ATE298343T1 (de) | Ligande für metabotropische glutamat-rezeptoren | |
| JP2003508453A5 (https=) | ||
| BRPI0411319A (pt) | compostos terapeuticamente ativos e sua utilização | |
| RO118870B1 (ro) | Monometansulfonat de acid (e)-alfa-[2-n-butil-1-[(4-carboxifenil)metil]-1h-imidazol-5-il]metilen-2-tiofenpropionic, procedee de preparare şi compoziţii farmaceutice | |
| MA29236B1 (fr) | Prevention et traitement de troubles thromboemboliques | |
| EP2066304A4 (en) | SYSTEMS, METHODS, AND COMPOSITIONS FOR TREATING AND USING AN AUDITOR | |
| WO2004080482A3 (en) | Use of angiotensin converting enzyme (ace) inhibitors to prevent diabetes in a subject with chronic heart failure | |
| EP1625207A4 (en) | COMPOUNDS FOR THE TREATMENT OF INFLAMMATION, DIABETES AND RELATED DISEASES | |
| MXPA06000705A (es) | Combinacion de antagonista del receptor 2 de glutamato metabotropico (mglur2) e inhibidor de acetilcolinesterasa (ache) para tratar trastornos neurologicos agudos y/o cronicos. | |
| MX340217B (es) | Metodo para el tratamietno y bioensayo que involucra el factor de inhibicion de migracion de macrofagos (mif), como un factor de depresion del miocardio, derivado del corazon. | |
| WO2007056324A3 (en) | Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent | |
| ZA200309965B (en) | Brake shoe for braking a cable. | |
| BR0008781A (pt) | Terapia combinada de inibidor de enzima conversora de angiotensina e antagonista de aldosterona epóxi-esteroidal para tratamento de doença cardiovascular | |
| WO2006048877A3 (en) | Treatment of b-cell malignancies with fgfr3 inhibitors | |
| CA2367107A1 (en) | Methods for limiting scar and adhesion formation |